We are live on ! Find out more
BAMS

Bellevue Asset Management (Switzerland) Portfolio holdings

AUM $656M
1-Year Est. Return 11.45%
This Fund
S&P 500
This Quarter Est. Return
-14.54%
1 Year Est. Return
+11.45%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$613M
AUM Growth
-$108M
Cap. Flow
+$11.4M
Cap. Flow %
1.86%
Top 10 Hldgs %
30.19%
Holding
150
New
11
Increased
47
Reduced
31
Closed
17

Top Buys

Rank Stock Value
1
SUPN icon
Supernus Pharmaceuticals
SUPN
+$5.95M
2
LRMR icon
Larimar Therapeutics
LRMR
+$3.76M
3
AMGN icon
Amgen
AMGN
+$3.65M
4
INSY
Insys Therapeutics, Inc.
INSY
+$3.31M
5
HALO icon
Halozyme
HALO
+$3.1M

Top Sells

Rank Stock Value
1
RCPT
RECEPTOS INC COM STK (DE)
RCPT
+$6.46M
2
CAH icon
Cardinal Health
CAH
+$3.59M
3
KITE
Kite Pharma, Inc.
KITE
+$3.49M
4
MDVN
MEDIVATION, INC.
MDVN
+$3.47M
5
ALKS icon
Alkermes
ALKS
+$3.33M

Sector Composition

Rank Sector Weight
1 Healthcare 91.86%
2 Financials 0.95%
3 Industrials 0.45%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HZNP
51
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$4.36M 0.71%
220,000
+70,000
+47% +$2.21M
ELV icon
52
Elevance Health
ELV
$86.2B
$4.2M 0.69%
30,000
– –
AGIO icon
53
Agios Pharmaceuticals
AGIO
$1.95B
$3.81M 0.62%
54,000
+13,000
+32% +$1.27M
BMY icon
54
Bristol-Myers Squibb
BMY
$132B
$3.55M 0.58%
60,000
– –
ALKS icon
55
Alkermes
ALKS
$8.29B
$3.46M 0.56%
59,000
-50,500
-46% -$3.33M
HALO icon
56
Halozyme
HALO
$12.2B
$3.3M 0.54%
246,000
+154,384
+169% +$3.1M
CERN
57
DELISTED
Cerner Corp
CERN
$3.3M 0.54%
55,000
– –
AKRX
58
DELISTED
Akorn Inc
AKRX
$3.21M 0.52%
112,470
-15,580
-12% -$644K
LRMR icon
59
Larimar Therapeutics
LRMR
$417M
$3.19M 0.52%
+8,333
New +$3.76M
HOLX
60
DELISTED
Hologic
HOLX
$3.17M 0.52%
81,000
– –
HCA icon
61
HCA Healthcare
HCA
$89.6B
$3.09M 0.5%
40,000
– –
MRK icon
62
Merck
MRK
$323B
$2.96M 0.48%
62,880
-10,480
-14% -$557K
XRAY icon
63
Dentsply Sirona
XRAY
$2.34B
$2.95M 0.48%
58,400
– –
LLY icon
64
Eli Lilly
LLY
$1.1T
$2.93M 0.48%
35,000
+15,000
+75% +$1.27M
ACHN
65
DELISTED
Achillion Pharmaceuticals
ACHN
$2.9M 0.47%
420,000
+44,000
+12% +$358K
MASI
66
DELISTED
Masimo
MASI
$2.89M 0.47%
75,000
– –
ARIA
67
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$2.89M 0.47%
495,000
– –
SRCL
68
DELISTED
Stericycle Inc
SRCL
$2.79M 0.45%
20,000
+5,000
+33% +$696K
COO icon
69
Cooper Companies
COO
$14.9B
$2.75M 0.45%
74,000
– –
VAR
70
DELISTED
Varian Medical Systems, Inc.
VAR
$2.73M 0.45%
42,194
-5,702
-12% -$416K
PFE icon
71
Pfizer
PFE
$154B
$2.67M 0.44%
89,590
-15,810
-15% -$507K
NKTR icon
72
Nektar Therapeutics
NKTR
$2.53B
$2.65M 0.43%
16,000
+2,667
+20% +$472K
NVDQ
73
DELISTED
Novadaq Technologies Inc.
NVDQ
$2.61M 0.43%
250,000
+174,402
+231% +$2.06M
NBIX icon
74
Neurocrine Biosciences
NBIX
$16.8B
$2.59M 0.42%
65,000
– –
ALNY icon
75
Alnylam Pharmaceuticals
ALNY
$29B
$2.57M 0.42%
32,000
-22,000
-41% -$2.44M
1 2
3
4 5

Similar funds

VFAM
Valley Forge Asset Management King Of Prussia, Pennsylvania $645M AUM 5.8% 1-Year Est. Return
MSU
Maple Securities USA Jersey City, New Jersey $672M AUM 1.03% 1-Year Est. Return
PSI
Pinnacle Summer Investments Fairfax, Virginia $678M AUM 9.5% 1-Year Est. Return
SFP
Santa Fe Partners Santa Fe, New Mexico $608M AUM 8.76% 1-Year Est. Return
MCM
Mazama Capital Management Portland, Oregon $544M AUM 9.52% 1-Year Est. Return
NMIS
Northwestern Mutual Investment Services Milwaukee, Wisconsin $525M AUM 2.45% 1-Year Est. Return
SM
Stratton Management King Of Prussia, Pennsylvania $824M AUM 1.57% 1-Year Est. Return
ZAM
Zenit Asset Management Stockholm, Sweden $450M AUM 8.32% 1-Year Est. Return

Bellevue Asset Management (Switzerland)'s Q3 2015 Portfolio in Review

As of Q3 2015, Bellevue Asset Management (Switzerland) held 150 positions worth $613M, down 15% from $721M the previous quarter. Its ten largest holdings account for 30% of the portfolio.

Bellevue Asset Management (Switzerland)'s Q3 2015 filing shows 11 new, 47 increased, 31 reduced and 17 closed positions. Its largest new stake was Supernus Pharmaceuticals: 320,000 shares worth $4.49M. The largest sale was RECEPTOS INC COM STK (DE), an estimated $6.46M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 90% a quarter earlier, followed by Financials and Industrials.

  • Bellevue Asset Management (Switzerland)'s largest Q3 2015 buy was Supernus Pharmaceuticals: 320,000 shares worth $4.49M.
  • Bellevue Asset Management (Switzerland) added most to Amgen in Q3 2015, an estimated $3.65M increase.
  • Bellevue Asset Management (Switzerland)'s biggest Q3 2015 reduction was Cardinal Health, cutting an estimated $3.59M.
  • Bellevue Asset Management (Switzerland) fully exited RECEPTOS INC COM STK (DE) in Q3 2015, selling an estimated $6.46M.
  • Bellevue Asset Management (Switzerland)'s ten largest holdings make up 30% of its $613M portfolio in Q3 2015.
  • Bellevue Asset Management (Switzerland) opened 11 new positions and closed 17 in Q3 2015.
  • Bellevue Asset Management (Switzerland)'s portfolio value fell 15% quarter-over-quarter to $613M.

Based on Bellevue Asset Management (Switzerland)'s 13F filing for Q3 2015, filed 12 Nov 2015.